Last reviewed 2026-04-22 · How we verify

Amosartan® tab

Amosartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor to reduce vasoconstriction and lower blood pressure.

Amosartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor to reduce vasoconstriction and lower blood pressure. Used for Hypertension, Diabetic nephropathy (in some markets).

At a glance

Mechanism of action

Amosartan binds to and blocks the angiotensin II type 1 (AT1) receptor on vascular smooth muscle and other tissues, preventing angiotensin II-mediated vasoconstriction and aldosterone release. This leads to vasodilation, reduced peripheral vascular resistance, and decreased blood pressure. The drug is used primarily for hypertension management and may provide renal and cardiovascular protection.

Approved indications

• Hypertension
• Diabetic nephropathy (in some markets)

Common side effects

• Dizziness
• Fatigue
• Hyperkalemia
• Cough
• Headache

Key clinical trials

• A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of UI15AML055MT and Amosartan® Tablet 5/50 mg After a Single Oral Administration in Healthy Male Volunteers (PHASE1)
• The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy. (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Amosartan® tab CI brief — competitive landscape report
• Amosartan® tab updates RSS · CI watch RSS
• Hanmi Pharmaceutical Company Limited portfolio CI